+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

This research aims to evaluate the effects of energy supplementation with carbohydrate-rich sports gels compared to a low-sugar sports drink in low-risk pregnant women receiving epidural analgesia during labor. The study addresses the increased metabolic demands of labor and investigates whether a carbohydrate solution improves maternal and newborn outcomes. It is a pilot randomized, triple-blind clinical trial involving 142 term pregnant women. Participants will be randomly assigned to receive either a high-carbohydrate sports gel or a low-carbohydrate hydrogel. The first dose is given 60 minutes after epidural analgesia, with subsequent doses every 3 hours during active labor, up to a maximum of four doses. Both interventions are prepared to look and feel identical and are administered orally. Water intake is encouraged throughout labor. During the study, participants will have their labor duration, obstetric and neonatal outcomes monitored. Additional assessments include cardiotocography patterns, maternal and neonatal blood glucose levels, postpartum hemorrhage, vomiting episodes, and maternal satisfaction. The study collects data from epidural administration until delivery and up to 24 hours postpartum, aiming to inform the design of future larger trials.

Age: 18Years +FEMALEPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
S

Actively Recruiting

Researchers are evaluating a continuity of care intervention aimed at improving metabolic control in adults with type 2 diabetes mellitus T2DM in the Terres de lEbre health region. This randomized, parallel-group clinical trial is led by the Endocrinology Service at Hospital de Tortosa Verge de la Cinta and focuses on training primary care professionals through structured, multidisciplinary education and feedback. The study addresses challenges in managing T2DM including glycemic control and cardiovascular risk, with HbA1c as the primary marker. The intervention involves onsite training sessions delivered by endocrinologists and nurse educators to primary care physicians and nurses at selected centers. Training consists of six modules combining theoretical and practical content related to diabetes management, cardiovascular risk reduction, and diabetic foot care. These sessions occur biweekly over one year from July 2025 to July 2026, with each participating center receiving 15 sessions. Centers are randomized to either receive this training or continue usual care without the specific continuity-of-care training. Participants with T2DM will be assessed at baseline, 6, 12, and 24 months for HbA1c and secondary health outcomes like cholesterol levels, blood pressure, BMI, and adherence to screening protocols. The study also collects professional feedback through focus groups before and after the intervention to understand barriers and facilitators. Data are anonymized, and the study aims to provide evidence on the effectiveness of multidisciplinary care continuity in a primary care setting over a two-year follow-up period.

Age: 18Years - 90YearsAll GendersPhase Not Applicable
12 locations
P

Actively Recruiting

This observational study focuses on pregnant women in their third trimester, aiming to understand how physical fitness and emotional well-being can help predict the type of birth they will have, such as natural vaginal birth, cesarean section, or medically assisted birth. The study also explores whether a womans physical activity and confidence during pregnancy influence her ability to breastfeed successfully for up to six months. Participants will perform two simple physical tests during a clinic visit a hand-grip strength test and a 30-second chair stand test. They will also complete surveys about their daily physical activity, feelings and fears related to childbirth, and confidence in managing the final stages of birth and pushing. Follow-up phone calls will be conducted one month and six months after birth to discuss breastfeeding progress. Throughout the study, researchers will measure the mode of birth at delivery and breastfeeding maintenance at one and six months postpartum. Participants will be asked about their physical activity and emotional state during pregnancy, and their breastfeeding experience after birth. The study is expected to run from June 2026 to December 2027, with primary data collection completing by June 2027.

Age: 18Years +FEMALE
1 location
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations
O

Actively Recruiting

This research aims to collect detailed information about patients with lung cancer and other thoracic tumors to better understand the disease and treatment outcomes. It focuses on individualizing treatment based on markers that predict response to chemotherapy and molecular inhibitors. The study addresses challenges such as poor prognosis, variability in diagnosis and treatment, and the need for improved early detection and prevention strategies across Europe and Spain. The study is observational and multicenter, gathering data both retrospectively and prospectively from patients diagnosed and treated by medical professionals including thoracic surgeons and oncologists. It includes multiple groups of patients based on the type of thoracic tumor, such as non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic cancer, and carcinoid cancer. There are no experimental treatments instead, it involves comprehensive data collection on patient characteristics and treatments. Participants provide information from their medical history and treatment records over up to 10 years. Researchers study epidemiological and therapeutic factors related to thoracic tumors by reviewing clinical data. The main outcome is to describe characteristics of these tumors in Spanish patients. The study involves no interventions or medications, focusing on observation and data analysis to inform future care and research.

All AgesAll Genders
79 locations
T

Actively Recruiting

Researchers are studying adults aged 18 to 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia Ph-negative ALL. The study evaluates treatment outcomes based on measurable residual disease MRD status and genetic testing done at the start. The goal is to tailor therapy after initial consolidation to improve survival and remission rates. Patients initially receive a four-drug induction chemotherapy regimen including vincristine, prednisone, pegylated asparaginase, and daunorubicin. Those who do not respond may receive a second induction with fludarabine, cytarabine, G-CSF, and idarubicin. Patients with good MRD clearance and favorable genetics continue with early and delayed consolidation, reinduction, and maintenance chemotherapy using pediatric-type protocols. Others may proceed to allogeneic hematopoietic stem cell transplantation alloHSCT. Participants will undergo regular assessments of MRD after induction and consolidation phases, along with monitoring for complete remission at 4 to 8 weeks. Researchers will track overall survival for 3 years. Safety and treatment responses are evaluated throughout, with ongoing follow-up. The total study duration includes treatment periods and observation to assess long-term outcomes under the guidance of the PETHEMA Foundation.

Age: 18Years - 60YearsAll GendersPhase Not Applicable
108 locations